|
|
|
|
|
|
|
|
|
|
According to World Health Organization (WHO) Multiple Sclerosis International Federation (MSIF) "Atlas of MS" 2013 estimates a prevalence rate in India is 5-20 per 100,000, which also seems an underestimate.
Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system (CNS), destroying the myelin and the axon in variable degrees. The disease is characterized initially by episodes of reversible neurologic deficits. In most patients, these episodes are followed by progressive neurologic deterioration over time. The cause of the disease is not known, but it likely involves a combination of genetic susceptibility and a nongenetic trigger, such as a virus, low vitamin D levels, or environmental factors, that together result in a self-sustaining MS is an inflammatory, demyelinating disease of the Central Nervous System.
Hence we at Nuvigen provide a treatment to control negative consequences & to improve the quality of life of patients living with Multiple Scelrosis
Botulinum neurotoxin is a very complex substance produced by bacteria. Botulinum neurotoxin attaches itself exclusively to nerve cells that activate the muscular system or specific glands – effectively and accurately blocking an overactive muscle or gland. The effect is reversible after a certain period of time (depending on dosage and injection location), so that repetition of the injection is typically necessary.
Spasticity occurs when part of the nervous system that controls muscle activity becomes damaged. The damage can arise from injury or a medical event such as a stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, spinal cord injury, brain tumor or brain damage, which may be caused by oxygen deficiency, encephalitis or meningitis. Overall, spasticity affects about 500,000 people in the United States and more than 12 million people throughout the world.
Dystonia is a neurological movement disorder characterized by involuntary muscle spasms and abnormal postures. Recent epidemiological studies indicate that there are more than 500000 people across Europe with some form of the disorder.
Every patient is unique and has individual therapeutic needs. Nuvigen strives to provide more good days to every patient by investigating novel and flexible neurotoxin treatment options. For patients with movement disorders associated with muscle spasms, such as blepharospasm and cervical dystonia, or with spasticity in the upper limbs after a stroke, individualized injection therapy with botulinum neurotoxin can mean a significant increase in quality of life.